{"id":980,"date":"2021-04-30T09:19:42","date_gmt":"2021-04-30T09:19:42","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=980"},"modified":"2021-04-30T09:19:42","modified_gmt":"2021-04-30T09:19:42","slug":"13-apr-2021-corticosteroids-patients-showed-non-significant-differences-in-vfd-compared-to-il-6r-antagonists","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/13-apr-2021-corticosteroids-patients-showed-non-significant-differences-in-vfd-compared-to-il-6r-antagonists\/","title":{"rendered":"(13 Apr 2021) Corticosteroids- patients showed non-significant differences in VFD compared to IL-6R antagonists"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and\/or Corticosteroid Therapy, the INTERACT study: A Multicenter International Observational Study<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.12.21255323v1<\/p>\n<p class=\"\">NCT04486521- A total of 860 patients met eligibility criteria: 589 received steroids, 170 IL-6R antagonists, and 101 combination therapy, and the groups were balanced after adjustment.&nbsp; The use of IL-6R antagonists alone or in combination was not associated with a significant difference in ventilator-free days (VFD) compared to steroids alone (adjusted incidence rate ratio [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL-6R antagonists (\u00df= 0.62, 95% CI \u22121.54, 2.78 for low-dose steroid; \u00df= \u22121.19, 95% CI \u22123.85, 1.47 for high-dose steroid). The use of IL-6R antagonists alone or in combination was not associated with a significant difference in 28-day mortality compared to steroids alone (adjusted odds ratio [95% CI]): IL-6R antagonists alone (0.68 [0.44,1.07]), combination (1.07 [0.67,1.7]). There was no difference in hospital mortality compared to steroids alone (aOR 0.68, 95% CI 0.43,1.09 for IL6-R antagonist, aOR 1.23, 95 % CI 0.72,2.11 for combination). We observed no difference in outcomes between mechanically ventilated adult ICU patients who received IL-6R antagonists, steroids, or combination therapy and those who received IL-6R antagonists or low- or high-dose steroids.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and\/or Corticosteroid Therapy, the INTERACT study: A Multicenter International Observational Study https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.12.21255323v1 NCT04486521- A total of 860 patients met eligibility criteria: 589 received steroids, 170&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/13-apr-2021-corticosteroids-patients-showed-non-significant-differences-in-vfd-compared-to-il-6r-antagonists\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(13 Apr 2021) Corticosteroids- patients showed non-significant differences in VFD compared to IL-6R antagonists&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,51],"tags":[52],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/980"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=980"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/980\/revisions"}],"predecessor-version":[{"id":981,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/980\/revisions\/981"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}